Hypermarcas (OTCMKTS:HYPMY) Sees Significant Decline in Short Interest

Hypermarcas (OTCMKTS:HYPMY) saw a significant drop in short interest during the month of October. As of October 15th, there was short interest totaling 1,675 shares, a drop of 60.7% from the September 30th total of 4,266 shares. Based on an average trading volume of 1,020,623 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy”.

Hypermarcas Stock Performance

Shares of OTCMKTS HYPMY traded down $0.10 during mid-day trading on Friday, hitting $3.89. The company had a trading volume of 9,617 shares, compared to its average volume of 307,313. The stock’s 50-day moving average price is $4.66 and its 200-day moving average price is $4.43. The company has a market capitalization of $2.74 billion, a price-to-earnings ratio of 7.78 and a beta of 0.65. The company has a current ratio of 1.86, a quick ratio of 1.26 and a debt-to-equity ratio of 0.50. Hypermarcas has a 1 year low of $3.39 and a 1 year high of $5.77.

Hypermarcas (OTCMKTS:HYPMY) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.14 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, sell-side analysts forecast that Hypermarcas will post 0.51 earnings per share for the current year.

Hypermarcas Company Profile

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company’s principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.